Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Surgical Outcome And Risk Scoring To Predict Survival After Hepatic Resection For Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

Surgical outcome and risk scoring to predict survival after hepatic resection for hepatocellular carcinoma with portal vein tumor thrombosis

Tae-Seok Kim1, Kwangho Yang2, Gi Hong Choi3

  • 1Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Keimyung University Dongsan Hospital, Daegu, Korea.

Annals of Hepato-Biliary-Pancreatic Surgery
|May 9, 2024

Related Experiment Videos

Author Spotlight: Advancing Liver Regeneration Research through ALPPS Mouse Model
06:45

Author Spotlight: Advancing Liver Regeneration Research through ALPPS Mouse Model

Published on: January 19, 2024

594
Application of the En Bloc Concept Combined with Anatomic Resection in Laparoscopic Hepatectomy
04:41

Application of the En Bloc Concept Combined with Anatomic Resection in Laparoscopic Hepatectomy

Published on: March 10, 2023

1.2K
Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience
09:51

Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience

Published on: December 4, 2023

1.1K

View abstract on PubMed

Summary
This summary is machine-generated.

Hepatic resection (HR) for hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) shows favorable survival outcomes. A new risk score effectively predicts prognosis and guides treatment for advanced HCC with PVTT.

Area of Science:

  • Hepatobiliary Surgery
  • Surgical Oncology
Keywords:
HepatectomyHepatocellular carcinomaPortal veinPrognosis

Related Experiment Videos

Author Spotlight: Advancing Liver Regeneration Research through ALPPS Mouse Model
06:45

Author Spotlight: Advancing Liver Regeneration Research through ALPPS Mouse Model

Published on: January 19, 2024

594
Application of the En Bloc Concept Combined with Anatomic Resection in Laparoscopic Hepatectomy
04:41

Application of the En Bloc Concept Combined with Anatomic Resection in Laparoscopic Hepatectomy

Published on: March 10, 2023

1.2K
Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience
09:51

Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience

Published on: December 4, 2023

1.1K
  • Gastroenterology

    • Background:

    • Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is advanced (BCLC stage C) with poor prognosis, typically managed with systemic therapy.
    • Current guidelines recommend systemic therapy for HCC with PVTT due to its advanced stage and poor prognosis.

    Purpose of the Study:

    • To evaluate surgical outcomes and long-term prognosis after hepatic resection (HR) in patients with HCC and PVTT.
    • To assess the efficacy of HR as a treatment option for advanced HCC with PVTT.

    Main Methods:

    • Retrospective analysis of 332 patients who underwent HR for HCC with PVTT.
    • Data collected from ten tertiary referral hospitals in South Korea.

    Main Results:

    • Median overall survival was 32.4 months; recurrence-free survival was 8.6 months.
    • 1-, 3-, and 5-year overall survival rates were 75%, 48%, and 39%, respectively.
    • A novel risk score (TIF score) using seven factors (tumor characteristics, inflammation, hepatic function) effectively stratified patient prognosis.

    Conclusions:

    • Hepatic resection offers favorable survival outcomes for selected patients with HCC and PVTT.
    • The developed risk scoring system is valuable for predicting prognosis and guiding treatment decisions in HCC with PVTT.
    Tumor thrombosis